GlassScriptPhysician profile
Reina Ocasio
NPI 1932177748
$1,368.15
in general payments reported to CMS, 2019-2025
18 companies · $1,266 in 2025
The $1,266 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $102 · 2025: $1,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,368.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $351.45 | 2025 | Minimed 780g |
| Novo Nordisk INC | $224.86 | 2025 | Ozempic, Rybelsus |
| Amgen INC. | $166.03 | 2025 | Tepezza, Evenity |
| Ascendis Pharma Endocrinology INC | $105.39 | 2025 | Yorvipath |
| Corcept Therapeutics | $76.61 | 2025 | Korlym |
| Abbott Laboratories | $70.85 | 2024-2025 | Freestyle Libre 3 |
| Averitas Pharma INC. | $54.44 | 2025 | Qutenza |
| Dexcom, INC. | $54.04 | 2024-2025 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $44.78 | 2025 | Isturisa |
| Shield Therapeutics INC | $44.71 | 2024 | |
| Lilly USA, LLC | $29.17 | 2025 | Mounjaro, Zepbound |
| Tandem Diabetes Care, INC. | $27.26 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Madrigal Pharmaceuticals | $26.02 | 2025 | Rezdiffra |
| Verity Pharmaceuticals INC. | $21.29 | 2025 | Tlando |
| Amneal Pharmaceuticals LLC | $19.25 | 2025 | Unithroid |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $18.16 | 2025 | Cequr Simplicity |
| Currax Pharmaceuticals LLC | $17.33 | 2025 | Contrave |
| Esperion Therapeutics, INC. | $16.51 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reina Ocasio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.